Chronic inflammatory bowel disease (IBD)—a category encompassing conditions such as ulcerative colitis and Crohn’s disease—represents one of the most persistent challenges in modern gastroenterology. Characterized by a relentless cycle of inflammation, these diseases do more than cause debilitating physical symptoms; they impose a significant burden on the quality of life of patients, many of whom are in the prime of their youth. For individuals between the ages of 15 and 29, the onset of these conditions often occurs during a critical window of personal growth, education, and the early stages of professional development. Now, a team of researchers at Charité – Universitätsmedizin Berlin has uncovered a crucial biological mechanism that drives these persistent inflammatory processes, offering a promising new direction for targeted clinical intervention. Their findings, which shed light on how specific immune messenger molecules fuel intestinal damage, have been published in the current issue of the journal Nature Immunology.
The clinical presentation of Crohn’s disease and ulcerative colitis is often as unpredictable as it is severe. Patients frequently endure cycles of remission and sudden, intense flare-ups characterized by agonizing abdominal cramps, persistent diarrhea, unexplained weight loss, and debilitating fatigue. Beyond the physical manifestations, the disease carries a heavy emotional toll, as patients struggle to manage symptoms that can strike without warning. The pathology of these conditions varies: while ulcerative colitis is typically localized to the inner lining of the large intestine, Crohn’s disease can affect the entire thickness of the intestinal wall and may manifest anywhere along the gastrointestinal tract, from the esophagus down to the colon. Because these diseases involve ongoing, systemic inflammation, they also carry the long-term risk of permanent tissue damage and an increased likelihood of developing bowel cancer.
For years, the standard approach to managing IBD has relied heavily on broad-spectrum immunosuppressants designed to dampen the immune system’s activity. While these treatments can be effective for many, they are not a panacea; they carry risks associated with general immune suppression and, crucially, fail to provide relief for a significant subset of patients. As medical science shifts toward precision medicine, the focus has moved away from generalized suppression toward the identification of specific signaling pathways. By blocking the precise messenger substances that drive inflammation, researchers hope to stop the disease at its source without compromising the patient’s overall immune health.
The complexities of IBD are rooted in a combination of genetic predisposition and environmental triggers, though the exact mechanisms that transform a healthy gut into a state of chronic inflammation have remained largely elusive. Prof. Ahmed Hegazy, a leading researcher at Charité’s Department of Gastroenterology, Infectiology and Rheumatology, has dedicated years to investigating the immune system’s defensive mechanisms within the gut. Through a rigorous, multi-year study, his team has successfully identified a toxic synergy between two key immune messenger proteins: Interleukin-22 (IL-22) and oncostatin M (OSM).
Under normal physiological conditions, Interleukin-22 plays a vital role in maintaining the integrity of the gut, supporting the cells that line the interior of the intestine and helping to preserve the protective mucosal barrier. However, the study suggests that in the context of chronic inflammation, this protein’s role is subverted. When paired with oncostatin M—a signaling molecule typically associated with tissue repair and cell differentiation—the result is an uncontrolled biological chain reaction.
"At the clinic, we mainly see young patients who are just beginning their professional lives," says Professor Hegazy. "So far, we have only been able to slow down the progression of the disease and alleviate symptoms. But not all patients respond well to existing treatments, so new therapeutic approaches are urgently needed."
The research team’s previous work had already highlighted the problematic nature of oncostatin M. Produced by specific immune cells, this protein acts as a catalyst for other inflammatory factors, effectively creating a feedback loop that triggers an excessive and destructive immune response. The researchers observed that patients with elevated levels of oncostatin M were frequently resistant to conventional therapies, suggesting that the molecule might serve not only as a driver of the disease but also as a biomarker to predict treatment failure. Identifying this pathway became the primary objective for the team, as they sought to understand how it could be pharmacologically interrupted.
Over the course of a five-year investigation, the researchers employed a variety of methodologies to map the signaling pathway of oncostatin M. Starting with animal models and progressing to the analysis of human tissue samples, the team examined the disease across its various stages. Using state-of-the-art single-cell sequencing, they discovered that in inflamed intestinal tissue, there is a significantly higher presence of cells expressing receptors for oncostatin M compared to healthy tissue. More alarmingly, they found that these receptors were present on a wider variety of cell types than previously expected.
The interaction between IL-22 and oncostatin M is particularly insidious. The research revealed that IL-22 actually increases the sensitivity of the gut lining to oncostatin M by promoting the expression of its receptors. "These two immune messengers work together and amplify the inflammation, drawing more immune cells into the intestine, like a fire that keeps getting more fuel and spreads," Professor Hegazy explains. By specifically blocking these binding sites for oncostatin M in their models, the researchers observed a marked reduction in both chronic inflammation and the subsequent development of cancer-related cellular changes.
The implications for cancer prevention are significant. In tissue samples obtained from patients who had developed colorectal cancer as a complication of their chronic intestinal inflammation, the researchers found a high density of oncostatin M receptors concentrated specifically around the tumors. These receptors were notably absent in the surrounding healthy tissue, suggesting that the signaling pathway does not merely facilitate inflammation but may actively drive the transformation of inflamed tissue into malignant growth.
However, the team emphasizes that the disease is highly heterogeneous. Chronic inflammation does not progress to cancer in every patient, and the clinical course of IBD varies wildly from one individual to another. This biological variability is precisely why IBD has been so difficult to treat and why universal treatment protocols often fall short.
"Chronic inflammatory bowel diseases are highly complex and differ from person to person," notes Prof. Britta Siegmund, Director of the Clinic for Gastroenterology, Infectiology and Rheumatology at Charité. "That’s exactly what makes them so difficult to treat and predict. Thanks to the role of oncostatin M and its amplifying interaction with interleukin-22, which we have now identified, we have a clearer understanding of what drives chronic inflammation in some patients. This opens up the door to developing and testing a new therapeutic approach."
The findings represent more than just a theoretical advancement; they are currently being translated into practical clinical applications. The research team is now working to develop targeted treatments that can disrupt the harmful synergy between IL-22 and oncostatin M. Given that these messengers are responsible for fueling the inflammatory process, inhibiting them could offer a lifeline to patients who have failed to respond to current biologics and other standard treatments.
"Our results provide a strong scientific basis for developing targeted treatments against this inflammation-promoting mechanism in chronic inflammatory bowel disease—particularly in patients with more severe forms of the illness," Professor Hegazy concludes. As a testament to the speed of this translational research, a clinical trial is already underway to test an antibody designed to block the receptors for oncostatin M. For the thousands of young people grappling with the uncertainties of Crohn’s and ulcerative colitis, this discovery marks a vital step forward in the quest to transform a lifelong, debilitating condition into one that is more manageable, predictable, and ultimately, treatable.